Clinical Trials Logo

Waldenstrom Macroglobulinemia clinical trials

View clinical trials related to Waldenstrom Macroglobulinemia.

Filter by:

NCT ID: NCT03364231 Completed - Clinical trials for Marginal Zone Lymphoma

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

NCT ID: NCT03332173 Completed - Clinical trials for Waldenström's Macroglobulinemia (WM)

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Start date: August 31, 2017
Phase: Phase 2
Study type: Interventional

This was a single-arm, multicenter Phase 2 study in Chinese participants with relapsed or refractory Waldenström's macroglobulinemia who exhibited one or more of the criteria for requiring treatment based on consensus guidelines from the Seventh International Workshop on Waldenström's Macroglobulinemia (IWWM). The study comprised an initial screening phase (up to 28 days), a single-arm treatment phase, and a follow-up phase.

NCT ID: NCT03329950 Completed - Breast Cancer Clinical Trials

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Start date: December 1, 2017
Phase: Phase 1
Study type: Interventional

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

NCT ID: NCT03187262 Completed - Clinical trials for Waldenström Macroglobulinemia

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

Start date: November 27, 2017
Phase: Phase 2
Study type: Interventional

This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.

NCT ID: NCT03053440 Completed - Clinical trials for Waldenström's Macroglobulinemia

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

ASPEN
Start date: January 25, 2017
Phase: Phase 3
Study type: Interventional

This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

NCT ID: NCT03019666 Completed - Multiple Myeloma Clinical Trials

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Start date: October 18, 2017
Phase: Phase 1
Study type: Interventional

This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.

NCT ID: NCT03010358 Completed - Anemia Clinical Trials

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Start date: July 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that has come back. Entospletinib may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Giving entospletinib and obinutuzumab together may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma.

NCT ID: NCT02962401 Completed - Clinical trials for Waldenstrom Macroglobulinemia

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

RemodelWM3
Start date: March 7, 2017
Phase: Phase 2
Study type: Interventional

Prospective national multicenter open label phase II Remodel WM3 trial

NCT ID: NCT02950220 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: January 12, 2017
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of ibrutinib when given together with pembrolizumab and to see how well they work in treating patients with non-Hodgkin lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Given pembrolizumab and ibrutinib may work better in treating patients with non-Hodgkin lymphoma.

NCT ID: NCT02933320 Completed - B-cell Lymphoma Clinical Trials

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

Start date: October 27, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to identify the tolerable dose of BI-1206 (both alone and in combination) for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206 alone and in combination with an anti-CD20 antibody.